Fox Jonathan C 4

What Happened
Jonathan C. Fox, a director of Edgewise Therapeutics, acquired 339 restricted stock units (RSUs) on April 1, 2026. The award is reported as an acquisition (code A) at $0.00 per share (no cash paid); the Form 4 does not state a cash value for the award. The filing notes these RSUs were granted and released as a Quarterly Retainer Award under the company's Outside Director Compensation Policy, as amended.

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (timely filing).
• Transaction type/code: Award/Grant (A).
• Shares acquired: 339 RSUs; reported price $0.00 (no cash consideration).
• Shares owned after transaction: not disclosed in the Form 4.
• Footnote: RSUs were granted and released pursuant to Section 2.4 of Edgewise’s Outside Director Compensation Policy, as amended.
• No indication of a 10b5-1 plan, cashless exercise, tax-withholding sale, or that the filing was late.

Context
This was a routine director compensation award (quarterly retainer) rather than an open-market purchase or sale. Such grants are common for outside directors and do not necessarily signal the director is buying or selling stock based on company prospects. The award was issued/released to the director on the same date per the policy language cited in the filing.